French company Enterome Bioscience has entered into two separate collaborations to further its research into the gut microbiome in a bid to address significant unmet medical needs, it has been announced.
The company has entered into strategic drug discovery collaborations with Japanese drug firm Takeda (TYO: 4502) and a subsidiary of Johnson and Johnson (NYSE: JNJ), Janssen Biotech.
The first agreement, with Takeda, will focus on the development of potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze